Contact: National offices: Graham Smith, Commercial Director Belgium Aegate Ltd Buro & Design Center Esplanade 1 box 98 1020 Brussels Tel: +44 1763 268 160 Email: [email protected] Tel: +32 2 290 34 00 Fax: +32 2 290 34 10 www.aegate.be Italy Aegate Ltd Via Venezia, 23 20099 Sesto San Giovanni (MI) Tel: +39 02 2412 6796 Fax: +39 02 2412 6794 www.aegate.it United Kingdom Aegate Ltd H9 The Courtyard Melbourn Science Park Melbourn Herts SG8 6HB UK Tel: +44 1763 268 160 www.aegate.com Aegate Holdings Ltd H9 The Courtyard Melbourn Science Park Melbourn Herts SG8 6HB UK Tel: +44 1763 268 160 www.aegate.com Aegate: experts in medicines authentication “ ” I’m delighted to have joined Aegate at this exciting time. The Falsified Medicines Directive will require the digitisation of the pharmaceutical supply chain and Aegate are well placed to work with the European and National stakeholders to deliver this. Aegate are currently scanning over 200,000 packs of medicine an hour and are experts in the field of medicines authentication. This expertise has been gained over the last decade and Aegate has invested over €65m during this time to get the process right. My experience of scaling systems and of working with ecosystem partners to deliver reliable fault tolerant services will be of great benefit as we look to expand the Aegate service into other European markets. The Aegate service is like an advanced communications services network, with high reliability and the ability to deal with complex protocols in a secure way with trusted service level agreements. Mark De Simone (CEO) 2 Brussels BELGIUM Sir David Cooksey (Chairman) “ What the Aegate system can do Aegate’s medicines authentication service has been protecting the European pharmaceutical supply chain since 2006. During this time, the Aegate system has alerted pharmacists to just under two million packs of recalled, expired or suspect medicines before they were dispensed to patients. The Aegate system is a highly secure, fully end-to-end service operating from manufacturer to dispensing point. Fully proven and operational, the Aegate service works in real-time with a rapid 250 millisecond round trip response time, checking every pack of medicine before it is dispensed and protecting patients from falsified medicines. ” Real-time action to recall suspicious packages Helping pharmacists deliver best practice to patients In June 2009 at 14.53, a package of medicine was dispensed without any problems at a pharmacy in the centre of Brussels. At 14.55, a package with an identical code was scanned 40 miles away at Namur and over the next ten minutes, 14 identical packages were scanned at different pharmacies throughout the country. In total 73 duplicates of the code were scanned in 69 different pharmacies. In September 2012, a study was carried out by the University of Leuven. Forty-two pharmacists participated. These were split into two groups; a control group (20 pharmacists) who received no training; and an intervention group (22 pharmacists) who received training in how to coach and follow osteoporosis patients in their use of Calcium. The code in question appeared to come from a manufacturer who was participating in the Aegate scheme. The manufacturer and regulator were informed and while an investigation was being carried out, a message on the system continued to alert pharmacists to the suspicious packages. It became clear that this was not a case of counterfeiting, but was due to a labelling error. As there was no quality issue with the product, a low level alert was issued to pharmacists and the manufacturer and regulator ensured there were no reimbursement issues. Due to the real time operation of the Aegate system, it is possible for the Aegate local country operator to contact the dispensing pharmacy immediately and order the pharmacist to retrieve a package from a patient. Unlike other systems, the Aegate operator knows the location of each terminal and can call the pharmacy in person, or send an urgent alert so that the pharmacist can retrieve the medicine from the patient before any harm is done. Medication records of 1161 osteoporosis patients were reviewed. A baseline, pre intervention, was recorded and results taken again at the end of the study. Following the training, every time a member of the intervention group dispensed an osteoporosis medication, The Aegate system delivered a message (via the dispensing software) that reminded the pharmacist of what they had learned during the training. The control group members did not receive this information. Results4: In the intervention group, 19.73% of patients at the start of the study were taking an optimal treatment regimen. At the end of the study, this percentage had increased to 44.9% (P=0.000001). 9.45% more patients received a correct dose of Calcium in the intervention group compared to the control group. Similarly 9.39% more patients received the correct dose of Vitamin D. Although this was not a example of counterfeiting, the real-time nature of the Aegate security system demonstrates that counterfeiters can, at best, hope to get away with selling only one copy of a fake drug. This clearly severely constrains their activities and improves patient safety. 4. Use of calcium and vitamin D supplementation in osteoporosis: study of the impact of counselling by the pharmacist - Veerle Foulon, Research Centre for Pharmaceutical Care and Pharmaco-economics, KU Leuven 7 Why choose Aegate? Aegate is one of the largest and most experienced specialised providers of medicine verification and authentication services in the World. Through integration with pharmacy Patient Medical Record (PMR) systems, Aegate services protect over 17 million patients across Europe. Since our inception in 2004, we have devoted considerable resources to developing and enhancing our specialist services. This investment in people, partnerships and systems enables us to consistently deliver to ‘six sigma’ quality standards. • • • 2 The Aegate system is a straightforward, universally applicable, authentication and traceability system for medicines. With a unique code affixed to each pack and a barcode scanner in the pharmacy, the Aegate system checks each pack of medicine against original data provided by the manufacturer and helps to ensure that patients are given only genuine and correct medicines. The Aegate system also offers Aegate takes patient safety seriously. We have invested €65 million in intellectual property to develop highly secure systems which check over 200,000 medicines an hour in real time. Benefiting from the lowest cost curve in the industry, Aegate also provides the highest quality service as measured against standards set by pharmacies. additional benefits such as improved product recall, more comprehensive adverse Aegate does not operate in isolation. Our ecosystem partner programme brings together 46 PMR suppliers and project management specialists who act as an extension to Aegate’s operations team, providing scalability when required. As stakeholders prepare for the implementation of the Falsified Medicines Directive, this partnership programme gives us the flexibility and scale required to act. Aegate is a specialist healthcare company with technical and security expertise. Our Aegate has specialist expertise. Together with our ecosystem partners Aegate can leverage over 1,000 specialists in this field; we are ready to implement the FMD in all Member States. This in depth knowledge allows us to de-risk the implementation of our service and its operation in pharmacy. No one else in Europe can count on such a large and specialised team. There is no substitute for practical experience, gained over a decade. Our medicine verification and authentication system is operational in multiple European countries, giving us a profound understanding of the challenges faced by companies as they prepare for the Falsified Medicines Directive. This first-hand expertise cannot be gained overnight and ensures we have access to the biggest specialised resources for the deployment of the Falsified Medicines Directive. Aegate has the competence and experience which is key to delivering the service required. events monitoring, up-to-the-minute drug safety advice and the opportunity for patient education and patient information at the point of dispense. experience in authenticating individual packages of medicines has been built up over a decade. Aegate has already completed installations with 33 different pharmacy systems, representing one-quarter of Europe’s 160,000 pharmacies. The system is fully compatible across national borders or regions. To date Aegate has checked 2.7 billion packs of medicine, whilst maintaining a round trip response time to pharmacies of 250 milliseconds. European Legislation European legislation was published on 1st July 2011 to protect EU citizens from the dangers of falsified medicines. This legislation became applicable on 2nd January How the Aegate system works Unique machine-readable product codes are affixed by the manufacturer to each box or pack of medicine and the data files containing these unique codes and other important security information are transferred securely to Aegate. At the pharmacy, the code is scanned and authenticated by Aegate software installed in the pharmacy system. No additional technology is required as the system is integrated into existing pharmacy software. The process of scanning and authentication is rapid and does not interrupt the dispensing process. 2013 in all European Member States. In parallel, the Commission have been working on the content of a Delegated Act to ensure the standardisation of the key safety features required by the legislation. The adoption and subsequent publication of this Delegated Act, will start a three year implementation timeline that will require the creation of the repository system (database) that will enable the verification of the authenticity of all prescription medicines and others considered to be at risk, at the point of dispense, in all Member States. Aegate’s end-to-end medicines authentication service fully meets the technical requirements outlined by the legislation and Aegate are fully supportive of the establishment and management by stakeholders of the repositories system with supervision by the relevant competent authorities. The Aegate system has been fully operational in Europe since 2006 and reliability tests under an independent audit carried out by the University of Leuven in 2008 achieved statistical significance. In 2011, the Aegate system was awarded ISO 27001, meaning that the security management system meets exacting standards relating to data back-up procedures, protection from viruses and hackers, security incident reporting, business continuity and contingency plans. The system is regularly stress-tested to ensure safety and continuity of supply. Customers can, therefore, be assured of a robust and secure service that meets demanding international standards. 6 3 How Aegate is improving the quality of medicines dispensed to patients Authentication of medicines Improving the recall process “With scanners in a growing number of pharmacies across Europe, Aegate is helping to eliminate the economic rewards to be gained from producing fake medicines” A recall may be needed to remove counterfeits from the market, or because of product defects, faulty packaging, or an unexpected safety issue. Recalling a medicine is costly and very difficult to achieve. High levels of publicity are required to alert pharmacists and consumers, with all the collateral damage this can have on the brand. Counterfeit and recalled drugs have a detrimental impact on patients, pharmacists and the pharmaceutical industry. They are a serious loss of revenue and may cause harm to patients, either through toxic ingredients or lack of efficacy. The new EU legislation requires pharmaceutical manufacturers to uniquely identify and tamper-proof their products, in order for these to be authenticated. These actions will substantially reduce the economic gains that can be achieved by counterfeiters. The AegatePROTECTTM system has been developed to make authentication straightforward and reliable for all members of the pharmaceutical supply chain. The Aegate security software compares each package with an original list supplied by the manufacturer and ensures that suspicious packages are identified before being handed to patients. Although authentication can be carried out at any point in the supply chain, the pharmacist is critical to success. Scanning in the dispensary takes each individual package out of the system, ensuring that no further copies of the same pack can be dispensed anywhere in Europe. 4 Current recall methods are highly inefficient. The MHRA (Medicines and Healthcare Products Regulatory Agency), noted that in 2007, only 40,000 out of 70,000 packs of counterfeit medicine were identified; it is not known what happened to the remainder1. In 2006, only seven out of 1,867 packs of fake Lipitor were recovered2. However, with a unique identifier on every single pack of medicine, the AegatePROTECTTM system can immediately confirm whether a product is the subject of a recall before being dispensed and pharmacists can rapidly scan their stock and identify recalled batches. Furthermore, with total cross-border compatibility, AegatePROTECTTM can identify all medicines subject to recall notices in any participating country. In 2013, the Aegate system enabled pharmacists to identify more than 18,000 recalled packs BEFORE dispensing. Pharmacists were also alerted to check the batch numbers of over 450,000 packs that may have been subject of a recall and a further 5,170 packs that were expired. 1 BBC News 3 Feb 2009 http://news.bbc.co.uk/1/hi/health/7865246.stm 2 The Sunday Times, September 23, 2007 Factory for fake prescription drugs http://www.timesonline.co.uk/tol/news/uk/health/article2511583.ece o.uk/tol/news/uk/health/article2511583.ece .uk/tol/news/uk/health/article2511583.ece AegateREACH™ Improving the services to patients Improving pharmacovigilance The Aegate product security system offers more than just an authentication service. As a medicine is scanned, the AegateREACHTM service can send prompts to the pharmacist, encouraging interventions designed to optimise correct usage or dosage. At the precise moment that the product is dispensed, the pharmacist can be prompted to talk to the patient about how to take the medicine, what side effects can be expected, or to deliver other educational messages. Pharmacist prompts can also be used to enrol patients for medication reminder services or to identify patients in need of a treatment review. The full safety profile of a medicinal product is often only known once the product is on the market. Some side effects, particularly if they occur rarely, only appear after long-term use or through interaction with other drugs. The new EU Pharmacovigilance directive encourages the reporting of adverse reactions both by healthcare professionals and patients, allowing patients to report adverse reactions directly to the competent authorities. AegateREACHTM has already been used to identify poorly controlled asthma patients; and was successfully used to refer patients back to their doctor to discuss a new formulation. Pharmacist intervention and counselling at the point of dispensation is highly effective and can increase treatment compliance by 15%.3 AegateREACHTM helps pharmacists to achieve best practice in their dealings with patients. With AegateASSURETM, the manufacturer can develop a plan in conjunction with the regulator to monitor adverse events (AEs). When a product that is being monitored under the black triangle scheme is scanned, the pharmacist can be prompted to question the patient about adverse events and an electronic link will enable the pharmacist or the patient to report any problems directly. This valuable service will enable more extensive and rapid reporting of AEs and facilitate the approvals and licensing process. Reimbursement The unique number affixed to each pack may also be used to support other healthcare systems such as reimbursement. When an item is scanned by the pharmacist, the authentication software can also generate an automatic signal for payment, ensuring that the pharmacist receives accurate payment for genuine dispensation of medicines. As each package can only be scanned once, this also has obvious advantages in limiting falsified claims for reimbursement. This has already been recognised by the EU legislation which notes that the same system that is used to authenticate a medicine can also be used to manage reimbursement. 3 E. Mehuys, L. Van Bortel, L. De Bolle, I. Van Tongelen, L. Annemans, J.P. Remon, and G. Brusselle Effectiveness of pharmacist intervention for asthma control improvement, Eur. Respir. J., Apr 2008; 31: 790-799 5 Contact: National offices: Graham Smith, Commercial Director Belgium Aegate Ltd Buro & Design Center Esplanade 1 box 98 1020 Brussels Tel: +44 1763 268 160 Email: [email protected] Tel: +32 2 290 34 00 Fax: +32 2 290 34 10 www.aegate.be Italy Aegate Ltd Via Venezia, 23 20099 Sesto San Giovanni (MI) Tel: +39 02 2412 6796 Fax: +39 02 2412 6794 www.aegate.it United Kingdom Aegate Ltd H9 The Courtyard Melbourn Science Park Melbourn Herts SG8 6HB UK Tel: +44 1763 268 160 www.aegate.com Aegate Holdings Ltd H9 The Courtyard Melbourn Science Park Melbourn Herts SG8 6HB UK Tel: +44 1763 268 160 www.aegate.com Aegate: experts in medicines authentication
© Copyright 2024